These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 28479365)

  • 1. Analysis of the Change in the Blood Concentration-Time Profile Caused by Complex Drug-Drug Interactions in the Liver Considering the Enterohepatic Circulation: Examining Whether the Inhibition Constants for Uptake, Metabolism, and Biliary Excretion Can be Recovered by the Analyses Using Physiologically Based Pharmacokinetic Modeling.
    Toshimoto K; Tomoda Y; Chiba K; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2727-2738. PubMed ID: 28479365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.
    Kusuhara H; Sugiyama Y
    Drug Metab Rev; 2010 Aug; 42(3):539-50. PubMed ID: 20175646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of enterohepatic recirculation in drug disposition: cooperation and complications.
    Malik MY; Jaiswal S; Sharma A; Shukla M; Lal J
    Drug Metab Rev; 2016 May; 48(2):281-327. PubMed ID: 26987379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
    Poirier A; Funk C; Scherrmann JM; Lavé T
    Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs.
    Sjögren E; Hedeland M; Bondesson U; Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():214-23. PubMed ID: 24075962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
    Patel M; Taskar KS; Zamek-Gliszczynski MJ
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.
    Li R; Maurer TS; Sweeney K; Barton HA
    AAPS J; 2016 May; 18(3):746-56. PubMed ID: 26951483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary excretion of drugs in man.
    Rollins DE; Klaassen CD
    Clin Pharmacokinet; 1979; 4(5):368-79. PubMed ID: 389528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling approach for multiple transporters-mediated drug-drug interactions in sandwich-cultured human hepatocytes: effect of cyclosporin A on hepatic disposition of mycophenolic acid phenyl-glucuronide.
    Matsunaga N; Suzuki K; Nakanishi T; Ogawa M; Imawaka H; Tamai I
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):142-8. PubMed ID: 25989889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion.
    Lai Y
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1175-87. PubMed ID: 19611403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting when biliary excretion of parent drug is a major route of elimination in humans.
    Hosey CM; Broccatelli F; Benet LZ
    AAPS J; 2014 Sep; 16(5):1085-96. PubMed ID: 25004821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
    Booth CL; Brouwer KR; Brouwer KL
    Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.
    Imawaka H; Sugiyama Y
    J Pharmacol Exp Ther; 1998 Mar; 284(3):949-57. PubMed ID: 9495854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer simulation of portal venous shunting and other isolated hepatobiliary defects of the enterohepatic circulation of bile acids using a physiological pharmacokinetic model.
    Cravetto C; Molino G; Hofmann AF; Belforte G; Bona B
    Hepatology; 1988; 8(4):866-78. PubMed ID: 3391514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of drugs subject to enterohepatic circulation.
    Chen HS; Gross JF
    J Pharm Sci; 1979 Jun; 68(6):792-4. PubMed ID: 458586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
    Yoshikado T; Yoshida K; Kotani N; Nakada T; Asaumi R; Toshimoto K; Maeda K; Kusuhara H; Sugiyama Y
    Clin Pharmacol Ther; 2016 Nov; 100(5):513-523. PubMed ID: 27170342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reversible clearance model for the enterohepatic circulation of drug and conjugate metabolite pair.
    Semmes RL; Shen DD
    Drug Metab Dispos; 1990; 18(1):80-7. PubMed ID: 1970782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug-Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method.
    Yoshida K; Maeda K; Konagaya A; Kusuhara H
    Drug Metab Dispos; 2018 Nov; 46(11):1805-1816. PubMed ID: 30135241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.